Lacosamide

[ Density]:
1.1±0.1 g/cm3

[ Boiling Point ]:
536.4±50.0 °C at 760 mmHg

[ Melting Point ]:
141-143?C

[ Molecular Formula ]:
C₁₃H₁₈N₂O₃

[ Molecular Weight ]:
250.294

[ Flash Point ]:
278.2±30.1 °C

[ Exact Mass ]:
250.131744

[ PSA ]:
67.43000

[ LogP ]:
0.90

[ Vapour Pressure ]:
0.0±1.4 mmHg at 25°C

[ Index of Refraction ]:
1.520

[ Symbol ]:

GHS02, GHS07

[ Signal Word ]:
Danger

[ Hazard Statements ]:
H225-H302 + H312 + H332-H319

[ Precautionary Statements ]:
P210-P280-P305 + P351 + P338

[ Hazard Codes ]:
F,Xn

[ Risk Phrases ]:
11-20/21/22-36

[ Safety Phrases ]:
16-26-36/37

[ RIDADR ]:
UN 1648 3 / PGII

[ WGK Germany ]:
2.0

Molecule of the month. Lacosamide.

Drug News Perspect. 17(10) , 689, (2004)

SPM-927 (Schwarz Pharma).

IDrugs 6(5) , 479-85, (2003)

Schwarz Pharma, under license from Harris FRC, is developing SPM-927, synthesized by researchers at the University of Houston, for the potential treatment of epilepsy and neuropathic pain.

Does SPM 927 have an analgesic effect in human neuropathic pain? An open label study.

Neurosci. Lett. 352(2) , 117-20, (2003)

The aim of the study is to establish if the putative anticonvulsant SPM 927 has an analgesic effect in human neuropathic pain and to assess its tolerability. This is an open label study of 25 adult hu...

More Articles